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1. Introduction
Dyspepsia is currently defined by Rome III criteria for the diagnosis of functional gastroin‐
testinal disorders (FGIDs), as the presence of one or more of the following symptoms: both‐
ersome postprandial fullness, early satiation, epigastric pain and epigastric burning [1] These
are symptoms thought to originate from the gastroduodenal region. Bloating and nausea often
coexist with dyspepsia but are considered nonspecific and are thus not included in the Rome
III criteria. However, there have been attempts by some researchers to broaden this definition
to include more symptoms. The Asian consensus guideline includes bloating, nausea, vomit‐
ing and belching in the definition of dyspepsia [2]
Dyspeptic patients who have not undergone any investigations are defined as having unin‐
vestigated dyspepsia. An organic cause is found in only a minority who seek medical care [3,
4]. The remaining group is labeled as having functional dyspepsia (FD). Organic dyspepsia
means there is a clear anatomic or pathophysiologic reason for the dyspeptic complaints, such
as peptic ulcer or cancer. In contrast, when a diagnosis of functional dyspepsia has been made,
it means that a number of investigations were performed including upper gastrointestinal
endoscopy, and were found to be normal [5].
The need for more systematic description of FGIDs gave rise to the Rome process, which has
evolved from Rome I in 1991 [6], Rome II in 1999 [7], to the most recent, which is Rome III [1].
According to Rome I and Rome II definitions, FD was defined as the presence of pain or
discomfort centered in the upper abdomen, in the absence of organic disease that readily
explained the symptoms [7]. While the meaning of pain is readily understood, the lack of an
accurate definition for discomfort was a major limitation of Rome I. Rome I also included reflux
symptoms in FD, and recognized a subgroup called “reflux-like dyspepsia”. Rome II tried to
correct this by excluding patients with predominant heartburn from the definition of FD. Rome
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I and Rome II criteria did not account for meal-related symptoms and this was the fundamental
change in Rome III criteria [8, 9].
Rome III criteria made a distinction between meal-induced symptoms and meal-unrelated
symptoms, and this forms the basis of newly defined subcategories of FD:
1. Meal-induced dyspeptic symptoms (postprandial distress syndrome, which is character‐
ized by postprandial fullness and early satiation)
2. Epigastric pain syndrome or EPS, characterized by epigastric pain and epigastric burning.
The traditional definition of FD portrays it as an idiopathic condition [10]. However, recent
studies suggest that this condition have some pathophysiologic correlates. A diversity of
changes in gastrointestinal structure and function has been described in this heterogeneous
disorder. In this chapter, the author attempts to provide an overview of structural and
physiological alterations in FD beyond those demonstrable by conventional tests used to
separate organic dyspepsia from its functional counterpart.
2. Current definition of Functional Dyspepsia
According to Rome III criteria, FD must include one or more of the following symptoms:
bothersome postprandial fullness, early satiation, epigastric pain and epigastric burning; with
no evidence of structural disease, including use of upper gastrointestinal endoscopy, which is
likely to explain the symptoms. Criteria should be fulfilled for at least 3 months with symptom
onset at least 6 months previously [1].
Older terms that represent FD are non-ulcer dyspepsia, idiopathic or essential dyspepsia. The
term non ulcer dyspepsia is still popular but no longer recommended because it implies that
the patient has symptoms similar to peptic ulcer disease without having an actual ulcer on
endoscopic examination. The spectrum of symptoms in FD includes epigastric pain syndrome
and postprandial distress syndrome
At least 3 months, with onset at least 6 months previously, of one or more of the following:





No evidence of structural disease (including upper endoscopy) that is likely to explain the symptoms.
Table 1. Rome III diagnostic criteria for functional dyspepsia [1]
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3. Definitions of functional dyspepsia symptoms [1]
The Rome III committee proposed a distinction between meal-induced symptoms and meal-
unrelated symptoms to be pathophysiologically, clinically and therapeutically relevant.
Epigastric pain syndrome:
1. Epigastric pain
Epigastric refers to the region between the umbilicus and lower end of the sternum, and
marked by the midclavicular lines. Pain refers to a subjective, unpleasant sensation; some
patients may feel that tissue damage is occurring.
2. Epigastric burning
Epigastric refers to the region between the umbilicus and lower end of the sternum, and
marked by the midclavicular lines. Burning refers to an unpleasant subjective sensation of heat.
Postprandial distress syndrome:
1. Postprandial fullness: An unpleasant sensation like the prolonged persistence of food in
the stomach.
2. Early satiation: A feeling that the stomach is overfilled soon after starting to eat, out of
proportion to the size of the meal being eaten, so that the meal cannot be finished.
Previously, the term ‘early satiety’ was used, but satiation is the correct term for the
disappearance of the sensation of appetite during food ingestion.
Recent research findings indicate that postprandial distress syndrome and epigastric pain
syndrome overlap in majority of patients with FD [11]. The implication of this is that the value
of dividing FD into the subgroups of postprandial distress syndrome and epigastric pain
syndrome is thus questionable [11]
4. Evaluating a patient with dyspepsia
4.1. Symptom-based diagnosis
The introduction of Rome criteria and Rome process was a milestone in the management of
FGIDs. However, the high turnover of Rome criteria is a testimony to the fact that symptom-
based diagnosis has limitations. Symptoms may be perceived differently within different
cultures and languages. It has been recommended that the current Rome III questionnaire be
translated into local languages [12]. Symptoms are poor predictors of FD and significant
overlaps are often seen with functional disorders including functional heartburn and irritable
bowel syndrome. [13-22].
One of the difficulties encountered in evaluating a patient with dyspepsia is that symptoms
are nonspecific and cannot accurately differentiate an organic process from a functional
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disorder. Neither clinical impression, nor computer models incorporating patient demograph‐
ics, risk factors, history items, and symptoms can distinguish between organic and functional
disease in patients referred for endoscopic evaluation of dyspepsia( [23].
There is also a high degree of overlap between FD symptoms and those of gastroparesis [1,
24-29]. In FD, the predominant sensation of early satiety was found to be closely associated
with impaired accommodation, although it was also present in more than 30% of patients with
delayed gastric emptying [26]. Nausea and vomiting, thought to be cardinal symptoms of
gastroparesis, are present in at least 20-50% of patients with FD [25, 30, 31]. Epigastric pain
thought to be a cardinal symptom of FD is also present in up to 90% of patients with gastro‐
paresis (GP) [32, 33]. Generally, common symptoms of gastric neuromuscular dysfunction are
nonspecific and cannot reliably predict the underlying pathophysiology [24-26, 34]. Further‐
more, recent research data indicate that rapid gastric emptying has been implicated in
functional dyspepsia symptoms, especially in the postprandial distress syndrome [35, 36].
Enhanced antral contractility, decreased duodenal feedback inhibition and impaired accom‐
modation represent the underlying mechanisms [37, 38].
The current approach is to view functional dyspepsia and idiopathic gastroparesis, not as
completely distinct disorders, but as a broad, continuous spectrum, with significant overlap.
It has been proposed that these 2 entities be reclassified under the umbrella term of functional
dyspepsia with or without disordered gastric emptying [39], to enable clinicians and research‐
ers to focus on predominant symptoms expressed by the majority of patients with this disorder.
4.2. Age
Older age is an important predictor for the presence of organic disease. The American
Gastroenterological Association recommends proceeding directly to endoscopy in patients
older than 55 years [40], however, there has been debate about a lower cut-off age of 35 to 45
years in men [41]. The optimal age threshold for endoscopy is unclear but 55 years seems a
reasonable cut-off because cancer is rare in younger patients but no age threshold is absolute
[42] Age specific thresholds to trigger endoscopic evaluation may differ by sex and locality [43,
44] Prompt endoscopy in patients over 50 years regardless of alarm status has been shown to
increase the proportion of curable cases of upper gastrointestinal malignancies by as much as
30% [45-47], but the cost-effectiveness of initial endoscopy in this age group for improving
survival of cancer patients is uncertain [47, 48]. Distinct upper gastrointestinal malignancy
incidence rates and various distributions of its topographical types in different populations
[49-52], as well as differences in Helicobacter pylori infection rates [53, 54] could partly explain
the variable results.
4.3. Alarm features
Alarm features include unintended weight loss, family history of upper gastrointestinal
cancer, gastrointestinal bleeding, progressive dysphagia, odynophagia, unexplained iron
deficiency anemia, persistent vomiting, palpable mass, lymphadenopathy and jaundice. These
features are useful in identifying high risk patients who need early endoscopy. The absence
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of alarm features makes the likelihood of finding important structural causes for dyspepsia
very low. However, a meta-analysis found that negative predictive value of alarm features
was poor (6%) [55]. Worse still, subjects with organic pathologies may also have FD. [56]
4.4. Helicobacter pylori testing
Testing for Helicobacter pylori in dyspepsia may be used to select the subgroup of dyspeptic
patients who have Helicobacter-related dyspepsia. The Asian consensus guideline posits that
this is strictly not a form of FD. Proponents of this argue that gastritis can now be identified
easily with advanced endoscopic techniques, and that Helicobacter pylori-dyspepsia is a form
of post-infectious FD [2]. Exclusion of Helicobacter pylori infection should be an important
part of diagnostic exercise in parts of the world where the burden of infection is high [2]. The
effect of Helicobacter pylori eradication on the amelioration of symptoms in patients with FD
has been evaluated in several large, well-designed, randomized controlled trials, but the results
were conflicting [57-61]. Eradication of Helicobacter pylori in FD appears to improve dyspeptic
symptoms more in the Chinese population than in Western populations [2]
4.5. Gastric accommodation and visceral hypersensitivity
The accommodation reflex is a vagally mediated volume response of the upper part of the
stomach after a meal. After ingestion of food, the gastric fundus spontaneously dilates and
begins to store food [62]. Impairment of this accommodation reflex is known to correlate well
with dyspeptic symptoms especially early satiation [63, 64]. Enhanced perception of physio‐
logical signals arising from the stomach (visceral hypersensitivity) is considered a hallmark of
functional gastrointestinal disorders including FD [65]. Such hypersensitivity can be repro‐
duced acutely by different types of mechanical gastric distension [66, 67]. However, it has not
been possible to conclusively identify the site and mechanisms underlying visceral hypersen‐
sitivity in FD.
Gastric barostat is gold standard for investigating gastric accommodation. It is however,
invasive, time-consuming and uncomfortable to patients. Newer techniques include single
photon emission computed tomography (SPECT) [64], 2- and 3- dimensional gastric ultra‐
sound [68] and magnetic resonance imaging [69]. These are noninvasive but their high cost,
sophistication and radiation exposure make them less attractive.
Drinking test is simpler [70]. It is based on the assumption that gastric volume is reduced with
impaired accommodation and therefore limits the drinking volume. This test has been
validated against the gastric barostat but the reproducibility is limited due to differences in
types of drink and rates of drinking. In general these tests are poorly associated with dyspeptic
symptoms and cannot predict a response to treatment in FD. Therefore they are not yet
available for routine clinical use.
4.6. Gastric emptying
Gastroparesis is a syndrome characterized by delayed gastric emptying in absence of me‐
chanical obstruction. Its causes include diabetes mellitus, post-surgical and idiopathic [71].
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Delayed gastric emptying occurs in 23-59% of patients with FD [72]. Research has shown that
delayed gastric emptying may be related to postprandial fullness and vomiting with symp‐
toms being more frequently found in female patients than in males [73-75]. Other studies have
failed to confirm any difference in the occurrence of FD symptoms between patients with
normal or delayed gastric emptying [76, 77]
Assessment of gastric emptying is commonly performed for such indications as nausea,
vomiting and dyspepsia. However, there is a poor correlation of symptoms to observed
abnormalities.
Techniques of gastric emptying include scintigraphy, which is the standard method in clinical
practice, but is associated with radiation exposure. Newer non-invasive methods include
wireless motility capsule and gastric emptying breath testing. Ultrasound, single-photon
emission computed tomography (SPECT) and magnetic resonance imaging (MRI) are pre‐
dominantly research tools.
4.7. Chemical hypersensitivity test
The duodenum is implicated in the pathophysiology of FD. Duodenal hypersensitivity and
abnormal responses to various substances have been observed in FD.
Duodenal hypersensitivity to lipid: Duodenal infusion of lipid in subjects with FD increased
gastric distension and symptoms in a dose-dependent fashion [78]. Symptom relief is achieved
with administration of Loxiglumide, a cholecystokinin A receptor antagonist and this suggests
that cholecystokinin release following a lipid stimulus is the mediator of gastric hypersensi‐
tivity in FD [79] Using cholecystokinin infusion as a challenge test is appealing [80] but is not
yet available for clinical use.
Buspirone challenge test [81] is another chemical hypersensitivity test. This chemical is a
serotonin 1A agonist that acts at the hypothalamic level to stimulate prolactin release. The
extent of prolactin release following Buspirone challenge is a reliable measure of central 5HT
sensitivity which can be impaired in patients with FD [82, 83].
Duodenal sensitivity to acid infusion: Studies on the presence of duodenal hypersensitivity
to acid in FD patients and its role in the pathophysiology of FD remain controversial. Samson
et al [84] reported that duodenal acid infusion induced nausea in a subset of FD patients, but
not in healthy controls, suggesting the presence of duodenal hypersensitivity to acid in FD
patients. However, other studies found that dyspeptic symptoms such as nausea could be
induced by duodenal acidification in healthy volunteers [85].
5. Empirical treatment
Therapeutic trial may be employed as a means of diagnosis. This has proved successful in the
management of GERD but the story in FD is entirely different because its pathogenesis is poorly
understood and there is no effective treatment. Also, there is often a substantial placebo effect.
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The new drug, Acotiamide, an acetylcholinesterase inhibitor is promising and has been shown
to be efficacious and safe in the elimination of meal-related FD symptoms [86]. Though not yet
approved for treatment of FD, it holds high promise as no adverse events were recorded.
5.1. Duodenal eosinophilia
Eosinophils and mast cells may be specifically recruited to the duodenum, altering sensation
and motility [87]. The duodenum, which is often ignored in the search for pathophysiologic
explanations for FD may be key to the symptom experience in FD. Mast cells induce eosinophil
migration and eosinophils activate mast cells [88]. Degranulation from mast cells and eosino‐
phils leads to neural stimulation and smooth muscle contraction, which in turn results in
gastrointestinal symptoms, such as abdominal pain and bloating [89]. While a significant
increase in mast cells has not been observed in the duodenum of patients with FD, duodenal
eosinophilia in FD has been described [90, 91]. This finding is exciting, because, in patients
undergoing endoscopy, duodenal biopsy is safe and easy to perform. This finding also has a
potential therapeutic implication which further research would unravel.
Putative test/Abnormality Comments/Pitfalls
Helicobacter pylori testing Useful in identifying patients who have Helicobacter pylori
– associated dyspepsia
Gastric accommodation test Several tests have been developed. Invasiveness, high cost,
patient discomfort and radiation exposure remain
challenges
Gastric emptying test Scintigraphy is currently available for clinical use.
Empirical treatment Not a viable option because of poorly understood
pathogenesis and lack of effective treatment
Duodenal eosinophilia Initial studies promising. Larger studies needed.
Duodenal acid infusion Results controversial
Duodenal lipid infusion Duodenal hypersensitivity to lipids consistently obtained
from most studies
Chemical hypersensitivity tests Several candidate chemicals at various stages of
development
Table 2. Summary of structural and functional abnormalities of the gastrointestinal tract in functional dyspepsia
In conclusion, dyspepsia is a very common clinical problem globally. Majority of patients with
this problem have FD, defined traditionally as dyspepsia in which investigations, including
upper gastrointestinal endoscopy fail to reveal a structural, biochemical or other pathophy‐
siologic reason for the symptom. The pathophysiology of FD remains poorly understood.
Recent information from research shows that there are structural and physiological changes
in FD that may hold the key to further understanding of the pathogenesis of this disease. These
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include Helicobacter pylori infection, abnormalities of gastric accommodation, abnormalities
of gastric emptying, duodenal eosinophilia duodenal hypersensitivity to acid and lipids. These
changes have prospects of being deployed in future for the diagnostic evaluation of FD. The
implication of this is that FD may not be idiopathic after all. Research is likely to shed more
light on this in future.
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